Research programme: chemokine receptor antagonists - Sanofi Genzyme

Drug Profile

Research programme: chemokine receptor antagonists - Sanofi Genzyme

Alternative Names: AMD 887; CXCR4 antagonists - Sanofi Genzyme

Latest Information Update: 16 Dec 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genzyme Corporation
  • Class
  • Mechanism of Action CCR5 receptor antagonists; CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Cancer; HIV infections; Rheumatoid arthritis

Most Recent Events

  • 07 Nov 2006 AnorMED has been acquired by Genzyme Corporation
  • 15 Jul 2005 This programme is still in active development
  • 01 Jun 2004 Data presented at the 17th International Conference on Antiviral Research (ICAR-2004) have been added to the Viral infections antimicrobial activity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top